Anzeige
Mehr »
Freitag, 27.03.2026 - Börsentäglich über 12.000 News
Milliardenmarkt Drohnen: Entsteht hier der nächste Tech-Champion?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
27.03.26 | 09:18
31,040 Euro
-0,86 % -0,270
Branche
Chemie
Aktienmarkt
NIKKEI-225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
30,48030,97010:30
0,0000,00010:13

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA ANNOUNCES BOD CANDIDATES CHANGE IN REPRESENTATIVE DIRECTOR AT UPCOMING SHAREHOLDERS MEETING4
MiTakeda targets $1.3B in cost savings in further restructuring7
MiTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::NEXT STEPS IN ITS TRANSFORMATION TO STRENGTHEN COMPETITIVENESS AND ACCELERATE FUTURE GROWTH OUTLOOK8
MiTAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer3
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
MiTakeda kündigt Transformation mit Einsparungen von 200 Mrd. JPY bis 2028 an23
MiEQS-Adhoc: Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness and Accelerate Future Growth Outlook1.287EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Other Takeda Pharmaceutical Company Limited: Takeda Announces Next Steps in its Transformation to Strengthen Competitiveness...
► Artikel lesen
DiAbivax hires commercial chief from Takeda to infuse Entyvio expertise into IBD launch prep31
18.03.Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio17
08.03.FDA Grants Priority Review for Takeda (TAK) and Protagonist's Rusfertide in PV Treatment16
04.03.Takeda plans to lay off 400 employees in US - report57
02.03.Alan Walshe Appointed General Manager of Takeda Canada13
02.03.TAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::TAKEDA AND PROTAGONIST ANNOUNCE U.S. FDA ACCEPTS NDA AND GRANTS PRIORITY REVIEW FOR RUSFERTIDE12
02.03.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer8
02.03.Takeda, Protagonist Win FDA Priority Review For Rusfertide In Polycythemia Vera477TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) and Protagonist Therapeutics, Inc. (PTGX) said Monday the U.S. Food and Drug Administration has accepted the New Drug Application...
► Artikel lesen
26.02.Protagonist plans to pocket $400M from Takeda rather than split US rusfertide profits17
23.02.Boston Scientific adds Starbucks CFO, Takeda CEO to board of directors23
20.02.Takeda Shares Down After Entyvio Shows Strong Results In Ulcerative Colitis Trial In Children, Shows Potential To Address Treatment Gaps16
13.02.Takeda sichert sich KI-Plattform von Biotech-Startup Iambic für Wirkstoffforschung27
11.02.Takeda downsizes Boston footprint amid consolidation effort22
10.02.FDA kicks off review of Takeda's narcolepsy hopeful33
Weiter >>
164 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2